|
rs339331
|
|
|
0.760 |
GeneticVariation |
BEFREE |
We successfully replicated the association of rs13385191 (located in the C2orf43 gene, P = 8.60×10(-5)), rs12653946 (P = 1.33×10(-6)), rs1983891 (FOXP4, P = 6.22×10(-5)), and rs339331 (GPRC6A/RFX6, P = 1.42×10(-5)) with prostate cancer.
|
22662242 |
2012 |
|
rs1983891
|
|
|
0.720 |
GeneticVariation |
BEFREE |
We successfully replicated the association of rs13385191 (located in the C2orf43 gene, P = 8.60×10(-5)), rs12653946 (P = 1.33×10(-6)), rs1983891 (FOXP4, P = 6.22×10(-5)), and rs339331 (GPRC6A/RFX6, P = 1.42×10(-5)) with prostate cancer.
|
22662242 |
2012 |
|
rs12653946
|
|
|
0.740 |
GeneticVariation |
BEFREE |
We successfully replicated the association of rs13385191 (located in the C2orf43 gene, P = 8.60×10(-5)), rs12653946 (P = 1.33×10(-6)), rs1983891 (FOXP4, P = 6.22×10(-5)), and rs339331 (GPRC6A/RFX6, P = 1.42×10(-5)) with prostate cancer.
|
22662242 |
2012 |
|
rs13385191
|
|
|
0.720 |
GeneticVariation |
BEFREE |
We successfully replicated the association of rs13385191 (located in the C2orf43 gene, P = 8.60×10(-5)), rs12653946 (P = 1.33×10(-6)), rs1983891 (FOXP4, P = 6.22×10(-5)), and rs339331 (GPRC6A/RFX6, P = 1.42×10(-5)) with prostate cancer.
|
22662242 |
2012 |
|
rs1447295
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We showed statistically significant association of the A allele of rs1447295 (OR [CI 95%] = 1.96 [1.37-2.81], P<0.0001) and the T allele of rs10090154 (OR [CI 95%] = 2.14 [1.41-3.26], P<0.0001) with CaP.
|
23628314 |
2014 |
|
rs10090154
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We showed statistically significant association of the A allele of rs1447295 (OR [CI 95%] = 1.96 [1.37-2.81], P<0.0001) and the T allele of rs10090154 (OR [CI 95%] = 2.14 [1.41-3.26], P<0.0001) with CaP.
|
23628314 |
2014 |
|
rs12757998
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We show an association between RNASEL SNP rs12757998 and outcome after radiation therapy for prostate cancer.
|
23382116 |
2013 |
|
rs16901979
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We report that rs7008482, which maps to the 8q24.13 region, is an additional independent prostate cancer risk variant (P = 5 x 10(-4)), and we also replicate the association of rs16901979 with prostate cancer (P = 0.002).
|
17978284 |
2007 |
|
rs7008482
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We report that rs7008482, which maps to the 8q24.13 region, is an additional independent prostate cancer risk variant (P = 5 x 10(-4)), and we also replicate the association of rs16901979 with prostate cancer (P = 0.002).
|
17978284 |
2007 |
|
rs12418451
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We provide confirmatory evidence of pleiotropic associations with melanoma for two SNPs previously associated with lung cancer, and provide suggestive evidence for a male-specific association with melanoma for prostate cancer variant rs12418451.
|
25789475 |
2015 |
|
rs17632542
|
|
|
0.750 |
GeneticVariation |
BEFREE |
We propose that rs17632542 may directly influence PrCa risk.
|
21465221 |
2011 |
|
rs119484086
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We produced recombinant human tRNase ZL's, which contain one to three amino-acid substitutions from three missense mutations (Ser217Leu, Ala541Thr, and Arg781His) that are associated with the occurrence of prostate cancer.
|
15863270 |
2005 |
|
rs5030739
|
|
|
0.090 |
GeneticVariation |
BEFREE |
We produced recombinant human tRNase ZL's, which contain one to three amino-acid substitutions from three missense mutations (Ser217Leu, Ala541Thr, and Arg781His) that are associated with the occurrence of prostate cancer.
|
15863270 |
2005 |
|
rs4880
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We previously reported a statistically significant interaction between circulating selenium levels, variants in the superoxide dismutase 2 gene (SOD2; rs4880), and risk of developing prostate cancer and presenting with aggressive prostate cancer.
|
20477822 |
2011 |
|
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We performed a retrospective analysis of germline DNA samples from Ashkenazi Jewish men and a comparison group of non-Ashkenazi men treated for prostate cancer at our institution to determine the prevalence of HOXB13 G84E mutation in prostate cancer patients of Ashkenazi Jewish heritage, an ethnic group common to the New York City area.
|
23475555 |
2013 |
|
rs1024611
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We performed a case-control study to analyze the frequencies of CCL2 (I/D, rs3917887), -2518 (A > G, rs1024611), and CCR2 (G > A, rs1799864) polymorphisms for prostate cancer (PCa) risk.
|
25266801 |
2015 |
|
rs3917887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We performed a case-control study to analyze the frequencies of CCL2 (I/D, rs3917887), -2518 (A > G, rs1024611), and CCR2 (G > A, rs1799864) polymorphisms for prostate cancer (PCa) risk.
|
25266801 |
2015 |
|
rs61886492
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We observed the protective role of H475Y variant in cancers [breast cancer; OR (95% CI): 0.81 (0.55-1.19), prostate cancer: OR (95% CI): 0.00 (0.00-0.66)], and in autism (OR (95% CI): 0.47 (0.21-1.03), whereas inflated risk was observed in CAD (OR (95% CI): 1.69 (1.20-2.37) and miscarriages [Maternal OR (95% CI): 3.26 (2.11-5.04); Paternal OR(95% CI): 1.99 (1.23-3.21)].
|
22310383 |
2012 |
|
rs7726159
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We observed an association of allele rs2853669 C with increased risk of prostate cancer (co-dominant model TC vs. TT OR = 1.65, P = 0.002; additive model OR = 1.42, P = 0.005; dominant model: OR = 1.64, P = 0.001) and allele rs7726159 A with reduced risk of this malignancy (сo-dominant model: AA vs. CC OR = 0.42, P = 0.002; additive model: OR = 0.69, P = 0.002; dominant model: OR = 0.67, P = 0.01; recessive model: OR = 0.48, P = 0.005).
|
25296732 |
2015 |
|
rs2853669
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We observed an association of allele rs2853669 C with increased risk of prostate cancer (co-dominant model TC vs. TT OR = 1.65, P = 0.002; additive model OR = 1.42, P = 0.005; dominant model: OR = 1.64, P = 0.001) and allele rs7726159 A with reduced risk of this malignancy (сo-dominant model: AA vs. CC OR = 0.42, P = 0.002; additive model: OR = 0.69, P = 0.002; dominant model: OR = 0.67, P = 0.01; recessive model: OR = 0.48, P = 0.005).
|
25296732 |
2015 |
|
rs1859962
|
|
|
0.770 |
GeneticVariation |
BEFREE |
We observed no association of the SNPs and the risk of developing PCa (OR 0.84, 95 % CI 0.30-2.38, p = 1.0 to rs1859962 and OR 1.94, 95 % CI 0.57-6.52, p = 0.28 to rs4430796), both sporadic and hereditary.
|
24627192 |
2014 |
|
rs3760511
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We link prostate cancer (PC) risk SNPs rs11649743 and rs3760511 with elevated HNF1B gene expression and allele-specific epigenetic silencing, and outline a mechanism by which common risk variants could effect functional changes that increase disease risk: functional assays suggest that HNF1B is a pro-differentiation factor that suppresses epithelial-to-mesenchymal transition (EMT) in unmethylated, healthy tissues.
|
27732966 |
2016 |
|
rs11649743
|
|
|
0.730 |
GeneticVariation |
BEFREE |
We link prostate cancer (PC) risk SNPs rs11649743 and rs3760511 with elevated HNF1B gene expression and allele-specific epigenetic silencing, and outline a mechanism by which common risk variants could effect functional changes that increase disease risk: functional assays suggest that HNF1B is a pro-differentiation factor that suppresses epithelial-to-mesenchymal transition (EMT) in unmethylated, healthy tissues.
|
27732966 |
2016 |
|
rs1800795
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We investigated the role of two functional polymorphisms, IL-6-174G>C (rs1800795) and IL-6-572C>G (rs1800796), in the development of prostate cancer.
|
26535651 |
2015 |
|
rs854560
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We investigated the association the nonsynonymous SNPs, Q192R and L55M, with prostate cancer risk in a nested case-control analysis of 1,268 cases and 1,268 matched controls from the American Cancer Society CPS-II Nutrition Cohort.
|
18500687 |
2008 |